| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powe...
Lake Street analyst Thomas Flaten maintains Evaxion (NASDAQ:EVAX) with a Buy and raises the price target from $6 to $11.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Buy and maintains $16 price t...
Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ power...
Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on ...
